REG - Oncimmune Hldngs PLC - ImmunoINSIGHTS commercial update

Oncimmune HoldingsAnnouncement

21/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211221:nRSU2676Wa&default-theme=true

RNS Number : 2676W  Oncimmune Holdings PLC  21 December 2021

21 December 2021

 

 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

ImmunoINSIGHTS commercial update

 

ImmunoINSIGHTS master service agreement ("MSA") signed with top 5 global
pharma company

 

Contract signed under MSA to provide autoantibody profiling of patients in
autoimmune trials

 

Contract signed with EORTC to profile autoantibodies in participants in
co-funded EORTC Melanoma Group and MSD EORTC1325/KEYNOTE-054 KEYTRUDA(®)
trial in melanoma

 

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics
group, today announces that the Company has signed further commercial
contracts within its ImmunoINSIGHTS pharma services business.

 

MSA and Commercial Contract Signed with Leading Global Pharmaceutical Company

 

Following the recent signing of a MSA with a leading global pharmaceutical company, the Company is pleased to report that it has signed a commercial contract to provide autoantibody biomarker services. A second contract has been agreed and is expected to be signed in the next few days. Both programmes are scheduled to complete and be invoiced by the end of FY2022 and the Company expects these programmes to lead to follow-on studies.

 

Under the first contract, Oncimmune will develop a multiplexed assay to
measure Immunoglobulin E (IgE) autoantibodies on its SeroTag(TM) platform for
planned autoimmune studies. In the second, pending contract, Oncimmune will
evaluate the autoantibody profiles of patient samples collected in an
autoimmune trial for chronic idiopathic urticaria1 ("CIU"). This study will
measure the autoimmune profile in chronic, idiopathic (meaning 'of unknown
cause') cases of CIU and aims to uncover insights that will support the
clinical development of a therapeutic for CIU.

 

Commercial Collaboration Agreement Signed with The European Organisation for
Research and Treatment of Cancer ("EORTC")

 

The Company has signed an autoantibody profiling collaboration with the EORTC,
an independent, non-profit cancer research organisation whose mission is to
coordinate and conduct international translational and clinical research to
improve the standard of cancer treatment for patients. The new research
project, co-funded with the EORTC Melanoma Group and MSD, will evaluate the
autoantibody profiles of patient samples collected in the ongoing phase 3
EORTC1325/KEYNOTE-054 trial investigating KEYTRUDA(®) (pembrolizumab), MSD's
anti-PD-1 therapy, as monotherapy for surgically resected, high-risk melanoma.

 

The project will explore autoantibody profiles as biomarkers of clinical
response in patients with melanoma recruited onto the EORTC1325/KEYNOTE-054
trial, which assessed pembrolizumab versus placebo in an adjuvant setting (in
which the drug is administered after surgery). Pembrolizumab is an immune
check point inhibitor ("CPI") with uses in over 15 types of cancer, including
for the treatment of melanoma skin cancer, non-small cell lung cancer, bladder
cancer and Hodgkin lymphoma.

 

The project will use the Company's SeroTag immuno oncology discovery array to
explore the response to therapy and the potential for immune related adverse
events ("irAEs") among patients treated with pembrolizumab, nivolumab and
ipilimumab. The utility of the Company's SeroTag immuno oncology discovery
array was previously reported when the results of a prior study were presented
at the American Society of Clinical Oncology ("ASCO") meeting in 2020.2 The
aim of this new research project is to explore whether autoantibody patterns
are associated with recurrence-free survival in the adjuvant setting.

 

Oncimmune has already studied autoantibodies in patients receiving CPI
therapy, including pembrolizumab, and this research project builds on this
scientific knowledge, expanding the discovery antigen set and focusing on
recurrence among patients treated with pembrolizumab in the adjuvant setting.

 

New Academic Collaborations expand use of ImmunoINSIGHTS Technology Platform
into CAR-T and CAR-NK Cell Therapies with New Academic Collaborations

 

Additionally, the Company is also in the final stages of agreeing two new
collaborations with world-leading US-based academic institutes. These new
collaborations will in part focus on new market segments for our existing
technology platform, including chimeric antigen receptor cell therapy cells
("CAR-T") and chimeric antigen receptor natural killer cells ("CAR-NK"). CAR-T
and CAR-NK cell therapies are some of the fastest growing segments in the
pharmaceutical market globally and represent significant clinical and
commercial growth opportunities for the ImmunoINSIGHTS business.

 

Dr Adam M Hill, CEO of Oncimmune said: "Earlier this month we reported on the
commercial momentum we have experienced in Q2 FY2022 and committed to update
investors on further commercial progress before the end of the calendar year.
We are therefore delighted to announce the signing of this MSA with a leading
global pharma group, which has enabled the awarding of a contract utilising
our ImmunoINSIGHTS autoantibody biomarker service and a second contract
expected to be signed in the next few days. We are also excited to have signed
the agreement with EORTC for a profiling collaboration for the important,
much-needed drug, KEYTRUDA.

 

"These agreements further demonstrate the applicability and significance of
our ImmunoINSIGHTS service to key players within both the pharmaceutical
industry and research field and represents another endorsement of the
capabilities of ImmunoINSIGHTS to contribute to medical innovation. We also
have forthcoming collaborations with two leading US-based academic
institutions within CAR-T and CAR-NK represent an exciting expansion of our
technology platform into these fast-growing markets.

 

"These contracts announced today and earlier this month underpin the
commercial momentum we are currently experiencing and we look forward to
building on this in the coming months."

 

(1) CIU, also known as hives, is a skin disease which is often caused by an
allergic reaction to food or drugs. In a small number of cases, the disease is
chronic and of unknown cause.

(2) Hassel, J.C., et al. (2020). Autoantibodies as predictors for survival and
immune-related adverse events in checkpoint inhibition therapy of metastasised
melanoma. J. Clin. Oncol. 38, 10011-10011.

 

For further information:

 

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

contact@oncimmune.co.uk (mailto:contact@oncimmune.co.uk)

 

Singer Capital Markets (Nominated Adviser and Joint Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

+44 (0)20 7496 3000

 

WG Partners (Joint Broker)

David Wilson, Nigel Barnes

+44 (0)203 705 9321

 

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

Oncimmune@fticonsulting.com (mailto:Oncimmune@fticonsulting.com)

+44 (0)20 3727 1000

 

 

About Oncimmune

 

Oncimmune is a leading immunodiagnostics developer, primarily focused on the
growing fields of immuno-oncology, autoimmune disease and infectious diseases.
Oncimmune has a diversified and growing revenue both from its portfolio of
diagnostic products to detect early-stage cancer and its contract discovery
and development service business whose platform delivers actionable insights
into therapies to the Company's pharmaceutical and biotech partners.

 

Our understanding of the immune system enables us to harness its sophisticated
response to disease to detect cancer earlier and to support the development of
better therapies. The key to improving cancer survival is early detection and
better selection for therapy. As a company, we are driven by our passion to
improve cancer survival and to give people extra time.

 

Oncimmune's ImmunoINSIGHTS platform enables life science organisations to
optimise drug development and delivery, leading to more effectively targeted
and safer treatments for patients. Oncimmune's immunodiagnostic technology,
EarlyCDT, can detect and help identify cancer on average four years earlier
than standard clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung,
targets a vast market estimated to grow to £3.8bn by 2024. With over 200,000
tests already performed for patients worldwide and its use being supported by
peer reviewed data in over 12,000 patients, we are poised to become an
integral component of future lung cancer detection programmes, globally.

 

Oncimmune's diagnostic products business is located at its laboratory facility
in Nottingham, UK and its ImmunoINSIGHTS service business at its discovery
research centre in Dortmund, Germany. The ImmunoINSIGHTS business development
team are based in the US and Europe and Oncimmune is seeking to replicate the
Dortmund facility in the US in the medium term.

 

For more information, visit www.oncimmune.com (http://www.oncimmune.com)

 

About the EORTC

 

The European Organisation for Research and Treatment of Cancer (EORTC) is a
non-governmental, non-profit organisation, which unites clinical cancer
research experts, throughout Europe, to define better treatments for cancer
patients to prolong survival and improve quality of life. Spanning from
translational to large, prospective, multi-centre, phase III clinical trials
that evaluate new therapies and treatment strategies as well as patient
quality of life, its activities are coordinated from EORTC Headquarters, a
unique international clinical research infrastructure, based in Brussels,
Belgium.

 

For further information, please visit www.eortc.org (about:blankwww.eortc.org)

 

What is ImmunoINSIGHTS?

 

The ImmunoINSIGHTS service business leverages Oncimmune's technology platform
and methodologies across multiple diseases, to offer life-science
organisations actionable insights for therapies across the development and
product lifecycle. Our core immune-profiling technology is underpinned by our
library of over eight thousand immunogenic proteins, one of the largest of its
kind. This helps identify trial participants and patients into clinically
relevant subgroups, enabling development of targeted and more effective
treatments.

 

What is SeroTag?

 

Oncimmune's proprietary biomarker discovery engine, which is leveraged in our
ImmunoINSIGHTS services to discover and validate novel biomarkers can help
stratify patients in multiple cancer indications and with different autoimmune
diseases.

 

This high-throughput, multiplex technology is based on one of the largest,
in-house protein libraries, as well as a unique, ever-growing repository of
disease data for indications including, but not limited to, autoimmune
diseases and cancer. As a result, SeroTag is helping to address and monitor a
number of challenges currently hindering the successful development and
broader application of both cancer immunotherapies and treatments for
autoimmune diseases.

 

The platform is being applied to discover and validate biomarkers and develop
precision diagnostic tools from minimally invasive liquid biopsies. SeroTag
analyses autoantibodies-some of the most stable analytes-and is used most
frequently for the identification of IgG isoforms, in addition to IgM and IgA,
from just a few drops of serum.

 

The SeroTag platform acts as the primary discovery engine that feeds into the
creation of Oncimmune's NavigAID(TM) disease-specific stratification panels.
These precision medicine tools which are enabling patient and disease
stratification and support therapeutic development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDFEMFASEFSEEE